🇺🇸 FDA
Pipeline program

Dupilumab

R668-ALG-16114

Phase 2 small_molecule completed

Quick answer

Dupilumab for Peanut Allergy is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Peanut Allergy
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials